September 16, 2005. Among companies reporting clinical results, Genmab A/S said its new leukemia drug showed efficacy, Genzyme reported Campath was beneficial against multiple sclerosis, Javelin Pharma said Dyloject decreased the intensity of pain by 30%, Esprit Pharma bought Metagen Pharma to build up its portfolio of urological drugs, Amgen won a label extension for Neulasta, Johnson & Johnson got an FDA OK for Remicade against ulcerative colitis, Novo Nordisk can add children onto the label of its meal-time insulin analogue, and Geron sold 8 million shares at a price of $9, about 10% below yesterday’s closing print. Biotech moved higher in the final hour, with the Centient Biotech 200 rising almost 10 points to end at 3889, a gain of .25%. More details...
